↓ Skip to main content

Dove Medical Press

Article Metrics

sLAG-3 in non-small-cell lung cancer patients’ serum

Overview of attention for article published in OncoTargets and therapy, August 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
reddit
1 Redditor

Readers on

mendeley
4 Mendeley
Title
sLAG-3 in non-small-cell lung cancer patients’ serum
Published in
OncoTargets and therapy, August 2018
DOI 10.2147/ott.s164178
Pubmed ID
Authors

Yayi He, Yan Wang, Sa Zhao, Chao Zhao, Caicun Zhou, Fred R Hirsch

Abstract

Anti-programmed cell death-1/programmed cell death ligand-1 monoclonal antibodies have been widely used in non-small-cell lung cancer (NSCLC), but not every patient can get benefits from them. Whether other molecular markers can predict the results of programmed cell death-1/programmed cell death ligand-1 inhibitors need to be explored. Lymphocyte-activation gene-3 (LAG-3) is another important immune checkpoint, which can inhibit tumor immunity. Soluble LAG-3 (sLAG-3) plays different functions from LAG-3. In this study, we detected the serum sLAG-3 level in NSCLC patients. sLAG-3 was detected in 247 hospitalized patients by enzyme-linked immunosorbent assay. Every sample was repeated three times. Two-hundred forty-seven hospitalized patients were enrolled in this study. Of them, 71 had benign diseases and 176 were NSCLC patients. sLAG-3 in NSCLC serum was correlated with NSCLC stage. The sLAG-3 levels were significantly higher in stage I-II NSCLC than in stage III-IV (p<0.001). The advanced NSCLC had the lower sLAG-3 expression. This might be related to the poor cancer immune response. Increasing sLAG-3 level might be a promising treatment in advanced NSCLC patients.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 2 50%
Other 1 25%
Unspecified 1 25%
Readers by discipline Count As %
Medicine and Dentistry 3 75%
Unspecified 1 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2018.
All research outputs
#9,638,128
of 12,555,036 outputs
Outputs from OncoTargets and therapy
#722
of 1,567 outputs
Outputs of similar age
#188,014
of 272,604 outputs
Outputs of similar age from OncoTargets and therapy
#27
of 48 outputs
Altmetric has tracked 12,555,036 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,567 research outputs from this source. They receive a mean Attention Score of 2.4. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,604 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.